Background: There is strong and well-documented evidence that socio-economic inequality
in cancer survival exists within and between countries, but the underlying causes of these …

Abstract Purpose of Review Acute myeloid leukemia (AML) is a costly disease, and its
impact is greater in developing countries (DC). We will review the current concept of what …

Clinical outcome of patients with acute myeloid leukemia (AML) is associated with
cytogenetic and molecular factors and patient demographics (eg, age and race). We …

Acute myeloid leukemia (AML) is a life-threatening malignancy that is more prevalent in the
elderly. Because the patient population is heterogenous and advanced in age, choosing the …

Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with
lower socioeconomic status (SES), People of Color (POC), and older adults. NT uptake …

Abstract We report 1-and 5-year survival after acute myeloid leukemia (AML) diagnosis and
early mortality within 30 days of systemic anticancer therapy (SACT) treatments, using …

Background The excess mortality observed in Acute Myeloblastic Leukaemia (AML)
patients, partly attributed to unequal access to curative treatments, could be linked to care …

Background With the increase in the number of long-term survivors, interest is shifting from
cancer survival to life and quality of life after cancer. These include consequences of long …

Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude
standard therapy in many settings, with “real world” patients under-represented in clinical …

Objectives The use of patient‐reported outcome (PRO) measured outside clinical trials is not
well defined. We report the first analysis of the prospective PRO study within the Swedish …